TCL Archive DCT Board Approves Three New BRMP RFAs For Immunologic Research, $1.5 Million A Year February 27, 1987
TCL Archive FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment. December 17, 2013
TCL Archive Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review. November 14, 2003
